GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » Shiller PE Ratio

Savara (Savara) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Savara Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Savara Shiller PE Ratio Historical Data

The historical data trend for Savara's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Shiller PE Ratio Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Savara Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Savara's Shiller PE Ratio

For the Biotechnology subindustry, Savara's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Savara's Shiller PE Ratio falls into.



Savara Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Savara's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Savara's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.11/129.4194*129.4194
=-0.110

Current CPI (Mar. 2024) = 129.4194.

Savara Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -4.200 100.560 -5.405
201409 -4.200 100.428 -5.412
201412 -3.500 99.070 -4.572
201503 -4.200 99.621 -5.456
201506 -4.200 100.684 -5.399
201509 -4.200 100.392 -5.414
201512 -4.200 99.792 -5.447
201603 -4.404 100.470 -5.673
201606 -1.970 101.688 -2.507
201609 -1.210 101.861 -1.537
201612 -1.400 101.863 -1.779
201703 -1.650 102.862 -2.076
201706 -0.900 103.349 -1.127
201709 -0.280 104.136 -0.348
201712 -0.230 104.011 -0.286
201803 -0.860 105.290 -1.057
201806 -0.370 106.317 -0.450
201809 -0.360 106.507 -0.437
201812 -0.290 105.998 -0.354
201903 -0.340 107.251 -0.410
201906 -0.570 108.070 -0.683
201909 -0.300 108.329 -0.358
201912 -0.720 108.420 -0.859
202003 -0.270 108.902 -0.321
202006 -0.160 108.767 -0.190
202009 -0.180 109.815 -0.212
202012 -0.230 109.897 -0.271
202103 -0.130 111.754 -0.151
202106 -0.070 114.631 -0.079
202109 -0.070 115.734 -0.078
202112 -0.070 117.630 -0.077
202203 -0.050 121.301 -0.053
202206 -0.060 125.017 -0.062
202209 -0.070 125.227 -0.072
202212 -0.070 125.222 -0.072
202303 -0.070 127.348 -0.071
202306 -0.070 128.729 -0.070
202309 -0.100 129.860 -0.100
202312 -0.090 129.419 -0.090
202403 -0.110 129.419 -0.110

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Savara  (NAS:SVRA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Savara Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Savara's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (Savara) Business Description

Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Executives
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance officer: Chief Financial Officer 422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt officer: Chief Medical Officer 208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121

Savara (Savara) Headlines

From GuruFocus

Savara Announces Resignation of Chief Medical Officer

By Business Wire Business Wire 08-26-2022

Savara to Participate in Three Upcoming Investor Conferences

By Business Wire Business Wire 11-09-2022

Savara Announces New Employment Inducement Grant

By Business Wire Business Wire 03-31-2023

Savara to Present at the Jefferies Healthcare Conference

By Business Wire Business Wire 06-02-2023

Savara Announces New Employment Inducement Grant

By Business Wire Business Wire 05-05-2023

Savara Announces New Employment Inducement Grant

By Business Wire Business Wire 01-20-2023